High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-02

Study Completion Date

2024-07-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live \>2500m on sleep disordered breathing

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension

NCT05089487

High Altitude Pulmonary Hypertension Sleep

COMPLETED NA

Study to Investigate Sleep Apnea Patients at Altitude

NCT00514826

Obstructive Sleep Apnea Syndrome

COMPLETED NA

Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders

NCT01621061

High Altitude Pulmonary Hypertension Sleep Apnea

COMPLETED

Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study

NCT06755840

Sleep Disordered Breathing (SDB) Sleep Apnea Cardiometabolic Diseases +2 more

RECRUITING

Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension

NCT01371669

Sleep Disorders

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA \>30 mmHg who permanently live at HA \>2500 m will have nocturnal respiratory sleep studies near their living altitude in Aksay at 3200 m and on night 1 and 6 at 760m after relocation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Altitude Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Each highlander with HAPH will be assessed for SDB at 3200 m and at 760 m according to a prospective study design

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Assessments at 3200 m and 760 m, respectively

Participants will have a SDB assessment near their resident altitude at 3200 m and after relocation to 760 m after 1 and 7 days

Group Type EXPERIMENTAL

SDB assessment

Intervention Type OTHER

SDB will be assessed by respiratory polygraphy according to clinical standards

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SDB assessment

SDB will be assessed by respiratory polygraphy according to clinical standards

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Permanently living \>2500 m
* HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
* Written informed consent

Exclusion Criteria

* Highlanders who cannot follow the study investigations,
* Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
* Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
* Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No